IL317182A - Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension - Google Patents

Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension

Info

Publication number
IL317182A
IL317182A IL317182A IL31718224A IL317182A IL 317182 A IL317182 A IL 317182A IL 317182 A IL317182 A IL 317182A IL 31718224 A IL31718224 A IL 31718224A IL 317182 A IL317182 A IL 317182A
Authority
IL
Israel
Prior art keywords
hypertension
rxfp1
modulators
heart failure
treating resistant
Prior art date
Application number
IL317182A
Other languages
Hebrew (he)
Inventor
Anders Gabrielsen
Jr Richard Thomas George
Kathleen Marie Connolly
Sami Ali Abdel Hafees Omar
Marcin Ufnal
Original Assignee
Astrazeneca Ab
Anders Gabrielsen
Jr Richard Thomas George
Kathleen Marie Connolly
Sami Ali Abdel Hafees Omar
Marcin Ufnal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Anders Gabrielsen, Jr Richard Thomas George, Kathleen Marie Connolly, Sami Ali Abdel Hafees Omar, Marcin Ufnal filed Critical Astrazeneca Ab
Publication of IL317182A publication Critical patent/IL317182A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL317182A 2022-06-07 2023-06-06 Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension IL317182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263365971P 2022-06-07 2022-06-07
PCT/EP2023/065045 WO2023237511A1 (en) 2022-06-07 2023-06-06 Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension

Publications (1)

Publication Number Publication Date
IL317182A true IL317182A (en) 2025-01-01

Family

ID=86851555

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317182A IL317182A (en) 2022-06-07 2023-06-06 Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension

Country Status (11)

Country Link
US (1) US20260069558A1 (en)
EP (1) EP4536206A1 (en)
JP (1) JP2025519410A (en)
KR (1) KR20250020502A (en)
CN (1) CN119486724A (en)
AU (1) AU2023284904A1 (en)
CA (1) CA3257296A1 (en)
IL (1) IL317182A (en)
MX (1) MX2024015079A (en)
TW (1) TW202416940A (en)
WO (1) WO2023237511A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260116187A (en) * 2023-11-17 2026-07-28 일라이 릴리 앤드 캄파니 RXFP1 receptor agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
AU2021395353B2 (en) * 2020-12-08 2024-08-29 Astrazeneca Ab 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure

Also Published As

Publication number Publication date
CA3257296A1 (en) 2023-12-14
MX2024015079A (en) 2025-01-09
JP2025519410A (en) 2025-06-26
TW202416940A (en) 2024-05-01
CN119486724A (en) 2025-02-18
KR20250020502A (en) 2025-02-11
AU2023284904A1 (en) 2025-01-23
US20260069558A1 (en) 2026-03-12
EP4536206A1 (en) 2025-04-16
WO2023237511A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
ES3066017T3 (en) Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hf-pef)
IL285436A (en) Composite scaffold for repair, restoration and regeneration of soft tissues
SG11202003971RA (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
CA223415S (en) Implantable artificial bronchus
IL314157A (en) Prosthetic heart valves
IL317936A (en) Prosthetic heart valves
HK40127095A (en) Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension
MX2024015079A (en) Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension
ZA202107513B (en) Compounds and compositions comprising the same for treating hypertension or heart failure
CA224776S (en) Winch
CA216672S (en) Dovetail decking panel
HK40065900A (en) Treating heart failure
ZA202200320B (en) Method for controlling radix saposhnikoviae root rot or leaf spot caused by alternaria
GB202507839D0 (en) Heart failure
GB202507142D0 (en) Peptide for treating heart failure
HK40064736A (en) Compounds and compositions comprising the same for treating hypertension or heart failure
HK40080740A (en) Methods of treating pulmonary arterial hypertension
HK40108887A (en) Methods of reducing the risk of heart failure
EP4326244A4 (en) Methods of reducing the risk of heart failure
AU2021900882A0 (en) Treatment methods for pulmonary arterial hypertension
PH32023050513S1 (en) Yachts
PH32023050512S1 (en) Yachts
GB202411390D0 (en) Heart valve commissure bridge for valve repair
GB202314641D0 (en) Treatment for batten disease
CA3272055A1 (en) Methods for treating pulmonary hypertension